抗体探索の世界市場 - 市場考察、競合情勢、市場予測（2032年）

世界の抗体探索の市場規模は、2024年に17億9,287万米ドルであり、2032年までに38億6,182万米ドルに達すると予測され、2025年～2032年の予測期間にCAGRで10.12%の成長が見込まれます。市場はがん、糖尿病、心血管・神経疾患などの慢性疾患の有病率の上昇によって拡大しています。モノクローナル抗体や細胞治療などの生物学的製剤は標的治療を提供するため、従来の医薬品よりも需要が高まっています。バイオテクノロジー企業や製薬企業による医薬品開発の増加と、より迅速で効率的な開発を目的に探索サービスをCROに委託する動向の高まりが、市場をさらに押し上げています。これらの要因は、2025年～2032年に市場が持続的に成長する強力な基礎となっています。

抗体探索の市場力学

慢性疾患の増加により、臨床試験市場のAI化が進むと予測されます。GLOBOCAN（2023）によると、2022年に約2,000万人の新規がん患者が報告され、この数は世界中で2045年までに3,260万人に増加すると予測されています。

世界保健機関（WHO）（2024）のデータによると、WHO Eastern Mediterranean Regionでは、2022年に78万8,000件を超えるがん診断が記録されました。この数字は、2045年までに約157万件に倍増すると予測されています。このようながん負担の増大は、生物学的製剤の需要を促進しています。生物学的製剤は、がん治療において特異性が高く、標的外毒性が低いため、従来の低分子医薬品よりも好まれています。抗体探索はこうした生物学的療法の開発に不可欠であるため、抗体探索市場は世界的に拡大しています。

同様に、世界の糖尿病負担は急速に増加しています。International Diabetes Federation（2023）が提供したデータによると、2021年に糖尿病を患っていた20～79歳の成人は約5億3,700万人で、この数は2030年までに6億4,300万人、2045年までに7億8,300万人に増加すると予測されています。このような糖尿病人口の増加は、革新的な生物学的製剤の開発に向け効率的な抗体探索サービスを必要とする先進治療に対する大きな需要を生み出し、市場成長を促進しています。

世界保健機関（WHO）（2024）によると、2023年、てんかんは世界中で約5,000万人が罹患し、もっとも一般的な神経疾患の1つとなっています。同様に、うつ病は依然として世界の健康上の大きな懸念です。WHO（2023）によると、2023年に世界中で推定2億8,000万人がうつ病を患っていました。神経疾患の有病率の増加により、生物学的製剤に由来する標的治療が必要とされ、市場成長を後押ししています。

高い選択性、疾患の進行を遅らせる可能性、従来の治療法よりも小さい副作用などによる、生物学的製剤に対する需要の伸びが、抗体探索市場の拡大に大きく寄与しています。Association for Accessible Medicines（2023）のデータによると、2022年に米国の処方箋の90%超がジェネリック医薬品またはバイオシミラー医薬品であふれていました。このような生物学的製剤への依存の高まりは、革新的な標的治療薬への需要を直接後押ししており、その結果、先進の抗体探索技術へのニーズが加速しています。新しい治療抗体の開発は、この需要を満たす中心的なものであり、抗体探索市場を力強い成長へと向かわせるものです。

これに対応するため、業界の主要企業は、抗体探索能力の強化を目的とした戦略的提携や研究パートナーシップへの注力を強めています。例えば2025年2月、Alloy Therapeutics Inc.はPfizerとの戦略的提携を発表し、特に既存技術では対応が困難な標的に対する強力で特異的かつ効果的な抗体を探索するPfizerの能力を向上させるために設計された次世代プラットフォームを共同開発することを発表しました。

しかし、抗体の開発・製造における複雑性や課題、抗体の開発と生産にかかる高いコストなどが、抗体探索市場の成長を制限する主な抑制要因となっています。

当レポートでは、世界の抗体探索市場について調査分析し、市場規模と予測、過去3年の製品/技術開発、市場の主要企業、利用可能な機会などの情報を提供しています。

目次

第1章 抗体探索市場レポートのイントロダクション

第2章 抗体探索市場のエグゼクティブサマリー

• 市場の概要

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 抗体探索市場の主な要因の分析

• 抗体探索市場の促進要因
• 抗体探索市場の抑制要因と課題
• 抗体探索市場の機会

第6章 抗体探索市場におけるポーターのファイブフォース分析

第7章 抗体探索市場の評価

• サービスタイプ別
  • 抗原・エピトープデザイン
  • 抗体スクリーニング・選択
  • 抗体エンジニアリング・最適化
  • 抗体特性評価・検証
  • その他
• 抗体タイプ別
  • モノクローナル抗体（mAbs）
  • 二重特異性抗体
  • 抗体薬物複合体
• 用途別
  • 治療
  • 診断
  • 研究
• 由来別
  • ヒト
  • ヒト化
• エンドユーザー別
  • バイオ医薬品企業、製薬企業
  • バイオテクノロジー企業
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 抗体探索市場の企業と製品のプロファイル

• Creative Biolabs
• AbCellera Biologics, Inc.
• Twist Biosciences
• Thermo Fisher Scientific Inc.
• Absci Corp.
• ProteoGenix
• Neoncorte Bio
• Antibody Design Labs
• Adimab
• GenScript
• Sino Biological, Inc.
• Carterra, Inc.
• WuXi AppTec
• Samsung Biologics
• Charles River Laboratories
• Lonza
• Aragen Life Sciences Ltd.
• Dr. Reddy's Laboratories Ltd.
• Biointron Biological Inc.
• AvantGen

第9章 KOLの見解

第10章 プロジェクトアプローチ

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Antibody Discovery Market in Global (2022-2032)
• Table 3: Antibody Discovery Market in Global by Service Type (2022-2032)
• Table 4: Antibody Discovery Market in Global by Antibody Type (2022-2032)
• Table 5: Antibody Discovery Market in Global by Application (2022-2032)
• Table 6: Antibody Discovery Market in Global by Source (2022-2032)
• Table 7: Antibody Discovery Market in Global by End-Users (2022-2032)
• Table 8: Antibody Discovery Market in Global by Geography (2022-2032)
• Table 9: Antibody Discovery Market in North America (2022-2032)
• Table 10: Antibody Discovery Market in the United States (2022-2032)
• Table 11: Antibody Discovery Market in Canada (2022-2032)
• Table 12: Antibody Discovery Market in Mexico (2022-2032)
• Table 13: Antibody Discovery Market in Europe (2022-2032)
• Table 14: Antibody Discovery Market in France (2022-2032)
• Table 15: Antibody Discovery Market in Germany (2022-2032)
• Table 16: Antibody Discovery Market in United Kingdom (2022-2032)
• Table 17: Antibody Discovery Market in Italy (2022-2032)
• Table 18: Antibody Discovery Market in Spain (2022-2032)
• Table 19: Antibody Discovery Market in the Rest of Europe (2022-2032)
• Table 20: Antibody Discovery Market in Asia-Pacific (2022-2032)
• Table 21: Antibody Discovery Market in China (2022-2032)
• Table 22: Antibody Discovery Market in Japan (2022-2032)
• Table 23: Antibody Discovery Market in India (2022-2032)
• Table 24: Antibody Discovery Market in Australia (2022-2032)
• Table 25: Antibody Discovery Market in South Korea (2022-2032)
• Table 26: Antibody Discovery Market in Rest of Asia-Pacific (2022-2032)
• Table 27: Antibody Discovery Market in the Rest of the World (2022-2032)
• Table 28: Antibody Discovery Market in the Middle East (2022-2032)
• Table 29: Antibody Discovery Market in Africa (2022-2032)
• Table 30: Antibody Discovery Market in South America (2022-2032)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Antibody Discovery Market in Global (2022-2032)
• Figure 3: Antibody Discovery Market in Global by Service Type (2022-2032)
• Figure 4: Antibody Discovery Market in Global by Antibody Type (2022-2032)
• Figure 5: Antibody Discovery Market in Global by Application (2022-2032)
• Figure 6: Antibody Discovery Market in Global by Source (2022-2032)
• Figure 7: Antibody Discovery Market in Global by End-Users (2022-2032)
• Figure 8: Antibody Discovery Market in Global by Geography (2022-2032)
• Figure 9: Antibody Discovery Market in North America (2022-2032)
• Figure 10: Antibody Discovery Market in the United States (2022-2032)
• Figure 11: Antibody Discovery Market in Canada (2022-2032)
• Figure 12: Antibody Discovery Market in Mexico (2022-2032)
• Figure 13: Antibody Discovery Market in Europe (2022-2032)
• Figure 14: Antibody Discovery Market in France (2022-2032)
• Figure 15: Antibody Discovery Market in Germany (2022-2032)
• Figure 16: Antibody Discovery Market in United Kingdom (2022-2032)
• Figure 17: Antibody Discovery Market in Italy (2022-2032)
• Figure 18: Antibody Discovery Market in Spain (2022-2032)
• Figure 19: Antibody Discovery Market in the Rest of Europe (2022-2032)
• Figure 20: Antibody Discovery Market in Asia-Pacific (2022-2032)
• Figure 21: Antibody Discovery Market in China (2022-2032)
• Figure 22: Antibody Discovery Market in Japan (2022-2032)
• Figure 23: Antibody Discovery Market in India (2022-2032)
• Figure 24: Antibody Discovery Market in Australia (2022-2032)
• Figure 25: Antibody Discovery Market in South Korea (2022-2032)
• Figure 26: Antibody Discovery Market in Rest of Asia-Pacific (2022-2032)
• Figure 27: Antibody Discovery Market in the Rest of the World (2022-2032)
• Figure 28: Antibody Discovery Market in the Middle East (2022-2032)
• Figure 29: Antibody Discovery Market in Africa (2022-2032)
• Figure 30: Antibody Discovery Market in South America (2022-2032)
• Figure 31: Market Drivers
• Figure 32: Market Barriers
• Figure 33: Marker Opportunities
• Figure 34: PORTER'S Five Force Analysis

Antibody Discovery Market by Service Type (Antigen & Epitope Design, Antibody Screening & Selection, Antibody Engineering & Optimization, Antibody Characterization & Validation, and Others), Antibody Type (Monoclonal Antibodies (mAbs), Bispecific Antibodies, Antibody Drug Conjugates, and Others), Application (Therapeutics, Diagnostics, and Research), Source (Human, Humanized, and Others), End-Users (Biopharmaceutical and Pharmaceutical Companies, Biotechnology Companies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of chronic diseases and increasing demand for biological therapies.

The antibody discovery market was valued at USD 1,792.87 million in 2024, growing at a CAGR of 10.12% during the forecast period from 2025 to 2032 to reach USD 3,861.82 million by 2032. The antibody discovery market is growing due to the rising prevalence of chronic diseases like cancer, diabetes, and cardiovascular and neurological disorders. Biologics such as monoclonal antibodies and cell therapies offer targeted treatment, driving demand over traditional drugs. Increased drug development by biotech and pharma firms, along with the growing trend of outsourcing discovery services to CROs for faster, efficient development, is further boosting the market. These factors are creating a strong foundation for sustained market growth from 2025 to 2032.

Antibody Discovery Market Dynamics:

The growing prevalence of chronic diseases is expected to drive AI in the clinical trial market. According to GLOBOCAN (2023), approximately 20 million new cancer cases were reported in 2022, with this number projected to rise to 32.6 million by 2045 around the world.

As per the data from the World Health Organization (2024), in the WHO Eastern Mediterranean Region, over 788,000 cancer diagnoses were recorded in 2022. This figure was anticipated to double to approximately 1.57 million cases by 2045. This escalating cancer burden is fueling demand for biologics, which are preferred over traditional small-molecule drugs due to their high specificity and lower off-target toxicity in cancer treatment. Antibody discovery is critical in the development of these biological therapies, thereby boosting the market of antibody discovery market across the world.

Similarly, the global diabetes burden is rising rapidly. The data provided by the International Diabetes Federation (2023), approximately 537 million adults aged 20-79 were living with diabetes in 2021, a number expected to increase to 643 million by 2030 and 783 million by 2045. This growing diabetic population is creating substantial demand for advanced therapies, which require efficient antibody discovery services for the development of innovative biologics, thereby driving the market growth.

According to the World Health Organization (2024), in 2023, epilepsy affected approximately 50 million people worldwide, making it one of the most common neurological disorders. Similarly, depression remains a major global health concern. As per WHO (2023), in 2023, an estimated 280 million people worldwide were living with depression. The increasing prevalence of neurological conditions requires targeted therapies derived from biologic sources, fueling the market growth.

The rising demand for biologic drugs, driven by their high selectivity, potential to slow disease progression, and reduced side effects compared to conventional therapies, is significantly contributing to the expansion of the antibody discovery market. According to data from the Association for Accessible Medicines (2023), more than 90% of prescriptions in the United States were filled with generic or biosimilar medicines in 2022, reflecting the widespread adoption of cost-effective biologic alternatives. This growing reliance on biologics is directly fueling demand for innovative, targeted therapies, which in turn is accelerating the need for advanced antibody discovery technologies. The development of novel therapeutic antibodies is central to meeting this demand, positioning the antibody discovery market for robust growth.

In response, key industry players are intensifying their focus on strategic collaborations and research partnerships aimed at enhancing antibody discovery capabilities. For example, in February 2025, Alloy Therapeutics Inc. announced a strategic collaboration with Pfizer Inc. to co-develop a next-generation platform designed to improve Pfizer's ability to discover potent, specific, and effective antibodies, particularly against targets that are challenging to address using existing technologies.

However, the complexities and challenges in antibody development and manufacturing, and high development & production costs of antibodies, among others, are some of the key constraints that may limit the growth of the antibody discovery market.

Antibody Discovery Market Segment Analysis:

Antibody Discovery Market by Service Type (Antigen & Epitope Design, Antibody Screening & Selection, Antibody Engineering & Optimization, Antibody Characterization & Validation, and Others), Antibody Type (Monoclonal Antibodies (mAbs), Bispecific Antibodies, Antibody Drug Conjugates, and Others), Application (Therapeutics, Diagnostics, and Research), Source (Human, Humanized, and Others), End-Users (Biopharmaceutical and Pharmaceutical Companies, Biotechnology Companies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the service type segment of the antibody discovery market, the antibody engineering & optimization category is estimated to account for the largest market share in 2024. The growth of this category is primarily driven by the rising demand for biologic drugs, where antibody engineering plays a critical role in enhancing therapeutic efficacy, safety, and manufacturability.

Antibody engineering involves the modification and refinement of antibodies to improve their functional properties for both therapeutic and diagnostic applications. This includes enhancing binding affinity and specificity to target antigens, increasing molecular stability and half-life, reducing immunogenicity, and optimizing production scalability. These modifications not only improve therapeutic performance but also ensure the antibodies are suitable for large-scale manufacturing and long-term storage, key factors for commercial success.

Antibody engineering and optimization support the development of advanced biologic formats such as bispecific antibodies, antibody fragments (Fab, scFv), nanobodies, and antibody-drug conjugates (ADCs). For example, humanization of murine antibodies helps minimize immune rejection, making therapies safer and more effective for clinical use. A notable case is Gazyva(R) (obinutuzumab), which was engineered to enhance antibody-dependent cellular cytotoxicity (ADCC) against CD20+ lymphoma cells, demonstrating the real-world therapeutic value of antibody optimization.

In response to increasing demand, key players are actively pursuing strategic collaborations to advance antibody engineering capabilities. In June 2025, MAbSilico announced an exclusive partnership with YntoAb Co., Ltd., a leading Korean CRO, to co-develop high-resolution 3D antibody structure prediction tools. This collaboration aims to enable advanced epitope-driven design and customized antibody engineering solutions. Similarly, in September 2024, Isogenica Ltd. and Axxam S.p.A. formed a partnership to deliver specialized VHH antibody engineering services tailored to the needs of biotechnology and pharmaceutical companies.

Furthermore, companies such as Creative Biolabs, ProteoGenix, and others are offering comprehensive antibody engineering services, further accelerating innovation and adoption in this space. Their contributions are playing a key role in positioning the Asia-Pacific region as a growing hub for advanced antibody discovery and development.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of antibody discovery across the globe.

North America is expected to dominate the overall antibody discovery market:

North America is expected to hold the largest share of the antibody discovery market in 2024, driven by several key factors. This dominance can be attributed to several key factors, including the rising prevalence of chronic diseases, substantial investments in R&D for advanced therapies, increasing demand for biologic treatments, a growing number of drug development activities by biotech and pharmaceutical companies, and the development of advanced technologies to efficiently create antibody-based drugs. Collectively, these elements are expected to sustain the region's leading position in the antibody discovery market.

As per the data from GLOBOCAN (2024) revealed that the number of new cancer cases in the U.S. reached 2,380,189 in 2022, with projections suggesting an increase to 2,791,752 cases by 2030. Data from the American Cancer Society (2025) states that approximately 2,041,910 new cancer cases are expected to be diagnosed in 2025 in the United States.

According to the American Heart Association (2024), approximately 9.7 million adults were living with undiagnosed diabetes, while 29.3 million have been diagnosed. Furthermore, 115.9 million Americans were reported to be dealing with pre-diabetes as of 2021. The rising cases of cancer and diabetes in North America are driving the growth of the antibody discovery market by increasing the demand for targeted and personalized therapies, where monoclonal antibodies play a crucial role in improving treatment outcomes. This growing disease burden is prompting greater investment in research and development to discover and optimize novel antibody-based treatments.

According to an article published by the Centers for Disease Control and Prevention (2024), approximately 6.2 million adults were suffering from heart failure in the United States in 2022. The prevalence of coronary heart disease (CHD) is also a major driver of market growth. According to CDC data from June 2024, around 20.5 million Americans were living with CHD as of 2022. Furthermore, an estimated 6.5 million individuals aged 40 and older were diagnosed with peripheral artery disease (PAD) in the same year. Such rising cases of cardiovascular conditions are creating the demand for targeted therapies, which can be developed through antibody discovery.

As per the data from the National Institute of Health (2023), in 2022, it was estimated that more than one in five adults were living with a mental illness (59.3 million), with 21 million people suffering from one major depressive disorder. Similarly, data from the Government of Canada (2023), in 2022, approximately 5 million people were suffering from mental disorders, including major depressive disorders, anxiety, seizures, among others. According to the Centers for Disease Control and Prevention (2024), in 2022, approximately 2.9 million adults aged 18 and older in the U.S. reported having active epilepsy. Such an increasing prevalence of neurological conditions is fueling the growth of the antibody discovery market, as there is a growing need for targeted biologic therapies to address complex disorders such as Alzheimer's, multiple sclerosis, and Parkinson's disease.

Key players are increasingly focusing on technological advancements to accelerate antibody discovery in the region. For example, in October 2024, Absci and Twist Bioscience announced a collaboration to design a novel antibody therapeutic using Absci's generative AI platform and Twist's synthetic DNA technology, combining AI-driven antibody design with high-throughput gene synthesis for efficient testing and validation.

Therefore, the growing incidence of chronic diseases, combined with rapid technological innovation and research partnerships among key players, is positioning North America as a leader in the antibody discovery market.

Antibody Discovery Market Key Players:

Some of the key market players operating in the antibody discovery market include Creative Biolabs, AbCellera Biologics Inc., Twist Bioscience, Thermo Fisher Scientific Inc., Absci Corp., ProteoGenix, Neoncorte Bio, Antibody Design Labs, Adimab, GenScript, Sino Biological, Inc., Carterra, Inc., WuXi AppTec, Samsung Biologics, Charles River Laboratories, Lonza, AvantGen, Aragen Life Sciences Ltd., Dr. Reddy's Laboratories Ltd., Biointron Biological Inc., and others.

Recent Developmental Activities in the Antibody Discovery Market:

• In June 2025, Infinimmune, a biotechnology company specializing in human-first antibody discovery and design, launched GLIMPSE-1, a protein language model trained exclusively on native human antibody sequences from millions of paired heavy and light chains of human memory B cells, marking a new approach to therapeutic antibody engineering based on the human adaptive immune system.
• In April 2025, Antibody Solutions announced that single plasma B-cell discovery services have been added to its exclusive Cellestive antibody discovery platform, complementing the existing discovery pathways for activated and memory B-cells.
• In February 2022, Adcentrx Therapeutics, a biotechnology company focused on accelerating antibody-drug conjugate (ADC) development, and AvantGen, a leader in yeast display technology for human antibody discovery and optimization, announced a three-year, multi-target partnership to discover antibodies for novel ADC therapeutic candidates.

Key takeaways from the antibody discovery market report study:

• Market size analysis for current antibody discovery market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the antibody discovery market.
• Various opportunities available for the other competitors in the antibody discovery market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current antibody discovery market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the antibody discovery market growth in the future?

Target audience who can benefit from this antibody discovery market report study

• Antibody discovery product providers
• Research organizations and consulting companies
• Antibody discovery-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in antibody discovery
• Various end-users who want to know more about the antibody discovery market and the latest technological developments in the antibody discovery market.

Frequently Asked Questions for the Antibody Discovery Market:

1. What is antibody discovery?

• Antibody discovery is the process of identifying and developing antibodies that specifically bind to target molecules involved in diseases. It involves techniques like hybridoma, phage display, or single B-cell screening to generate and optimize candidate antibodies. These antibodies are then evaluated for their potential use in diagnostics, therapeutics, or research.

2. What is the market for antibody discovery?

• The antibody discovery market was valued at USD 1,792.87 million in 2024, growing at a CAGR of 10.12% during the forecast period from 2025 to 2032 to reach USD 3,861.82 million by 2032.

3. What are the drivers for the antibody discovery market?

• The antibody discovery market is growing due to the rising prevalence of chronic diseases like cancer, diabetes, and cardiovascular and neurological disorders. Biologics such as monoclonal antibodies and cell therapies offer targeted treatment, driving demand over traditional drugs. Increased drug development by biotech and pharma firms, along with the growing trend of outsourcing discovery services to CROs for faster, efficient development, is further boosting the market. These factors are creating a strong foundation for sustained market growth from 2025 to 2032.

4. Who are the key players operating in the antibody discovery market?

• Some of the key market players operating in the antibody discovery market include Creative Biolabs, AbCellera Biologics Inc., Twist Bioscience, Thermo Fisher Scientific Inc., Absci Corp., ProteoGenix, Neoncorte Bio, Antibody Design Labs, Adimab, GenScript, Sino Biological, Inc., Carterra, Inc., WuXi AppTec, Samsung Biologics, Charles River Laboratories, Lonza, AvantGen, Aragen Life Sciences Ltd., Dr. Reddy's Laboratories Ltd., Biointron Biological Inc., and others.

5. Which region has the highest share in the antibody discovery market?

• North America is expected to hold the largest share of the antibody discovery market in 2024, driven by several key factors. This dominance can be attributed to several key factors, including the rising prevalence of chronic diseases, substantial investments in R&D for advanced therapies, increasing demand for biologic treatments, a growing number of drug development activities by biotech and pharmaceutical companies, and the development of advanced technologies to efficiently create antibody-based drugs. Collectively, these elements are expected to sustain the region's leading position in the antibody discovery market.

Table of Contents

1. Antibody Discovery Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Antibody Discovery Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Antibody Discovery Market Key Factors Analysis

• 5.1. Antibody Discovery Market Drivers
  • 5.1.1. The growing prevalence of chronic diseases
  • 5.1.2. Rising demand for biologic therapies
  • 5.1.3. A growing number of drug development activities among biotech companies and pharmaceutical firms
• 5.2. Antibody Discovery Market Restraints and Challenges
  • 5.2.1. Complexities and challenges in antibody development and manufacturing
  • 5.2.2. High development & production costs of antibodies
• 5.3. Antibody Discovery Market Opportunity
  • 5.3.1. Advances in areas of gene editing, molecular biology, and others are facilitating the development of antibody drugs.
  • 5.3.2. Integration of advanced technologies such as artificial intelligence-assisted antibody design, predictive analytics, among others

6. Antibody Discovery Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Antibody Discovery Market Assessment

• 7.1. By Service Type
  • 7.1.1. Antigen & Epitope Design
  • 7.1.2. Antibody Screening & Selection
  • 7.1.3. Antibody Engineering & Optimization
  • 7.1.4. Antibody Characterization & Validation
  • 7.1.5. Others
• 7.2. By Antibody Type
  • 7.2.1. Monoclonal Antibodies (mAbs)
  • 7.2.2. Bispecific Antibodies
  • 7.2.3. Antibody Drug Conjugates
  • 7.2.4. Others
• 7.3. By Application
  • 7.3.1. Therapeutics
  • 7.3.2. Diagnostics
  • 7.3.3. Research
• 7.4. By Source
  • 7.4.1. Human
  • 7.4.2. Humanized
  • 7.4.3. Others
• 7.5. By End-Users
  • 7.5.1. Biopharmaceutical and Pharmaceutical Companies
  • 7.5.2. Biotechnology Companies
  • 7.5.3. Others
• 7.6. By Geography
  • 7.6.1. North America
    • 7.6.1.1. United States Antibody Discovery Market Size in USD million (2022-2032)
    • 7.6.1.2. Canada Antibody Discovery Market Size in USD million (2022-2032)
    • 7.6.1.3. Mexico Antibody Discovery Market Size in USD million (2022-2032)
  • 7.6.2. Europe
    • 7.6.2.1. France Antibody Discovery Market Size in USD million (2022-2032)
    • 7.6.2.2. Germany Antibody Discovery Market Size in USD million (2022-2032)
    • 7.6.2.3. United Kingdom Antibody Discovery Market Size in USD million (2022-2032)
    • 7.6.2.4. Italy Antibody Discovery Market Size in USD million (2022-2032)
    • 7.6.2.5. Spain Antibody Discovery Market Size in USD million (2022-2032)
    • 7.6.2.6. Rest of Europe Antibody Discovery Market Size in USD million (2022-2032)
  • 7.6.3. Asia-Pacific
    • 7.6.3.1. China Antibody Discovery Market Size in USD million (2022-2032)
    • 7.6.3.2. Japan Antibody Discovery Market Size in USD million (2022-2032)
    • 7.6.3.3. India Antibody Discovery Market Size in USD million (2022-2032)
    • 7.6.3.4. Australia Antibody Discovery Market Size in USD million (2022-2032)
    • 7.6.3.5. South Korea Antibody Discovery Market Size in USD million (2022-2032)
    • 7.6.3.6. Rest of Asia-Pacific Antibody Discovery Market Size in USD million (2022-2032)
  • 7.6.4. Rest of the World (RoW)
    • 7.6.4.1. Middle East Antibody Discovery Market Size in USD million (2022-2032)
    • 7.6.4.2. Africa Antibody Discovery Market Size in USD million (2022-2032)
    • 7.6.4.3. South America Antibody Discovery Market Size In USD Million (2022-2032)

8. Antibody Discovery Market Company and Product Profiles

• 8.1. Creative Biolabs
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. AbCellera Biologics, Inc.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Twist Biosciences
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Thermo Fisher Scientific Inc.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Absci Corp.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. ProteoGenix
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Neoncorte Bio
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Antibody Design Labs
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Adimab
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. GenScript
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Sino Biological, Inc.
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Carterra, Inc.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. WuXi AppTec
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Samsung Biologics
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Charles River Laboratories
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Lonza
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Aragen Life Sciences Ltd.
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Dr. Reddy's Laboratories Ltd.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Biointron Biological Inc.
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. AvantGen
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us